Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures
Sponsor: United Therapeutics
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from United Therapeutics
- Pulmonary Arterial Hypertension · Dec 2024
- Persistent Pulmonary Hypertension of the Newborn · Phase PHASE2 · May 2023
- Cardiovascular Diseases · Phase PHASE3 · Apr 2023
- Chronic Obstructive Pulmonary Disease · Phase PHASE3 · Oct 2022
- Combined Pulmonary Fibrosis and Emphysema · Phase PHASE2/PHASE3 · Aug 2021
Other Critical Limb Ischemia trials with similar outcome
This PHASE3 trial investigates Critical Limb Ischemia and Foot Ulcers and is currently terminated or withdrawn. United Therapeutics leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- United Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .